时间标签：数据日期 2026-10-31 · 生成时间 2026-11-01 05:30（Asia/Shanghai）｜ 检索窗口 PubMed edat 2026/10/28–2026/10/31 ｜ 情报发生日期 2026-10-31
研究问题
Furthermore, drug-resistant infections pose a significant challenge in cirrhosis [], with their prevalence increasing from 29 to 38% between 2011 and 2018 [].；However, considerable concern remains regarding the long-term effect of antibiotic prescriptions on AMR [, ].；However, a significant reduction in plasma ammonia between baseline and day-30 was observed in those treated with FMT [].
方法
Secondary objectives:To evaluate the efficacy of encapsulated FMT to reduce non-acute decompensating episodes of cirrhosis including new-onset or worsening grade of ascites and covert hepatic encephalopathy (West Haven criteria grade 0–1) [].To evaluate the impact of encapsulated FMT on patient outcomes including all-cause hospitalisation, disease progression (including development of acute-on-chronic liver failure), quality of life, mental health, alcohol use and survival.To assess the impact of FMT on antibiotic usage and loss/reduction of AMR genes.To evaluate the safety of encapsulated FMT.；Secondary endpoints (over a 24-month follow-up period):Time to first infection resulting in hospitalisation.Incidence of any decompensating episode of cirrhosis, including hepatic encephalopathy, new-onset or worsening ascites or variceal bleeding.Incidence of all-cause infection, including infect
核心结论
It is estimated that 10–20% of the UK population are at risk of developing CLD [].；Overt systemic inflammation with concurrent functional immunodeficiency is exhibited in cirrhosis, a phenomenon termed cirrhosis-associated immune dysfunction (CAID), resulting in an increased propensity to infection and higher likelihood of resultant complications [].；Furthermore, drug-resistant infections pose a significant challenge in cirrhosis [], with their prevalence increasing from 29 to 38% between 2011 and 2018 []. ‖ 结论：Rather than simply increasing microbial diversity, FMT may re-establish key metabolic networks, improve gut barrier integrity and recalibrate immune responses [, , ], mechanisms that may collectively reduce systemic inflammation and the risk of decompensating events.
局限
Further work has revealed that FMT may also increase gut-microbial richness and reduce carriage of enteric pathogens, intestinal barrier damage, and systemic inflammation [].；Patients who undergo liver transplantation will no longer receive IMP due to the lack of robust safety data of FMT administration in immunocompromised patients post liver transplantation.
对本项目的价值
★★☆☆☆ 干预证据决定参照标准效应量——任何抗衰干预的收益至少应对标该基线。设计 double-blind、phase 3。
全文来源
PMC JATS 全文（正文 44,647 字符，已过标题/DOI 逐字归属校验）
原文题录
- 英文标题：PROMISE: a PROspective randomised double-blind parallel group placebo-controlled multicentre trial of faecal MIcrobiota tranSplantation to improve outcomEs in patients with cirrhosis over 24 months-study protocol for a clinical trial.
- 期刊与标识：Trials · PMID 42947250 · DOI 10.1186/s13063-026-09914-x
C 级证据分级：C 级（预印本 / 观点评论，非原始研究）
本文属观点/评论类文献，不是原始研究。其论点依赖于作者对既有证据的梳理与判断，不构成新的实验证据。本站标注 C 级即为此意——阅读时请把它当作「领域内的思考框架」，而非「研究发现」。
关于本文的文献来源：本站依据 IMA 知识库「五刊监控·深度文献卡片」撰写，依据已获取的期刊全文（方法、样本量与结论已回到原文核对）；未能获取全文的同批条目另行标注「摘要级」，全程未做任何数值推算补全。